Management patterns and outcomes of patients with venous thromboembolism in the usual community practice setting

Clinical Therapeutics
Vincent J WilleyAlex C Spyropoulos

Abstract

The objectives of this study were to observe a commercially insured sample diagnosed with a venous thromboembolism (VTE) event and treated postevent with warfarin and to detail the thromboembolic and bleeding outcomes in the time periods during warfarin therapy and after discontinuation of such therapy. This retrospective, observational cohort study used medical, pharmacy, and eligibility data from 2 US health plans. Study inclusion required an inpatient diagnosis of deep venous thrombosis (DVT) or pulmonary embolism (PE) between January 1, 1998, and December 31, 2000; warfarin, heparin, or low-molecular-weight heparin within 30 days after diagnosis; no VTE diagnosis; and no anticoagulant use for 3 months preceding diagnosis. A random sample of medical charts was abstracted to validate VTE events and collect prothrombin time/international normalized ratio (INR) result data. Recurrent VTE events, bleeding events, and proportion of time within INR range were captured in the postindex VTE event time period. Univariate and multivariate statistical techniques were used to assess outcomes. A total of 2,090 patients were identified with a newly diagnosed VTE event (DVT only, 1450; PE with or without DVT, 640). Mean (SD) age was 61.7 (...Continue Reading

References

Nov 19, 1992·The New England Journal of Medicine·D P BrandjesJ W ten Cate
Mar 19, 1966·Lancet·R J Kernohan, C Todd
Jul 1, 1996·Annals of Internal Medicine·P PrandoniM H Prins
Dec 12, 1996·The New England Journal of Medicine·J S Ginsberg
Sep 4, 1997·The New England Journal of Medicine·UNKNOWN Columbus InvestigatorsR Baildon
Oct 20, 1998·Archives of Internal Medicine·L HarrisonJ Hirsh
Sep 8, 2000·Stroke; a Journal of Cerebral Circulation·A EvansL Kalra
Oct 30, 2001·American Journal of Epidemiology·S SchneeweissR J Glynn
Jan 15, 2002·Journal of Vascular and Interventional Radiology : JVIR·Matthew S Johnson
Sep 24, 2002·Vascular and Endovascular Surgery·Brenda K ZierlerD Eugene Strandness
Dec 13, 2002·Seminars in Vascular Surgery·Monica S Da Silva, Michael Sobel
Jan 22, 2003·Seminars in Thrombosis and Hemostasis·Sylvia K Haas
Dec 4, 2003·JAMA : the Journal of the American Medical Association·Alan S GoDaniel E Singer

❮ Previous
Next ❯

Citations

Apr 20, 2006·Journal of Thrombosis and Thrombolysis·Chaitanya SarawateOle Hauch
Jul 11, 2012·Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete·M Hahn, V Hach-Wunderle
Mar 16, 2007·Journal of General Internal Medicine·Cary P GrossHarlan M Krumholz
May 14, 2008·Southern Medical Journal·José María Calvo-Romero, Esther María Lima-Rodríguez
Sep 3, 2013·The New England Journal of Medicine·Harry R BüllerPhil Wells
Nov 5, 2013·Thrombosis Research·Alexander T CohenMeredith M P Gurwith
Jul 2, 2014·Current Medical Research and Opinion·Robert J WalterDavid Jiménez
Oct 28, 2015·Current Medical Research and Opinion·Paolo Prandoni
Aug 13, 2011·Thrombosis and Haemostasis·Charles E MahanAlex C Spyropoulos
Jul 14, 2010·Pharmacoepidemiology and Drug Safety·Sean HennessyBrian L Strom
Jan 25, 2012·Pharmacoepidemiology and Drug Safety·Leonardo TamarizVinit Nair
Jul 29, 2010·Congestive Heart Failure·Steven M Dean, William Abraham
Jan 27, 2015·The Clinical Respiratory Journal·Franco Piovella, Diana Irina Iosub
May 6, 2015·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Sebastian WerthJan Beyer-Westendorf
Apr 13, 2010·Journal of the American College of Cardiology·Robert S EpsteinJ Russell Teagarden
Aug 28, 2015·Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·Rakesh R SinghBrady S Moffett
Jan 26, 2012·Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·Arlene M GallagherTjeerd-Pieter van Staa
Oct 13, 2006·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Alex C Spyropoulos
May 8, 2009·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Deborah A CiosCraig I Coleman
Sep 25, 2010·Nature Reviews. Cardiology·Sarina A van der Zee, Jonathan L Halperin
Nov 8, 2015·Drugs·Matt Shirley, Sohita Dhillon
May 11, 2021·TH Open : Companion Journal to Thrombosis and Haemostasis·Jan Beyer-WestendorfMartin Bornhäuser
Jun 15, 2021·Frontiers in Cardiovascular Medicine·Guangguo FuZhongkai Wu

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.